Vol.

No.

June 21, 2024Jun 21, 2024

DOWNLOAD THE PDF

Cover Story

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

Capitol Hill

House GOP leaders propose “streamlining” NIH into 15 institutes and centers
Plan calls for slashing ARPA-H, adding oversight to infectious disease research

By Matthew Bin Han Ong

Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi

Free Obituary

Nathan Berger, founding director of Case Comprehensive Cancer Center, dies at 83

By Case Comprehensive Cancer Center

Cancer History Project Free

Remembering the day 22 years ago when ODAC debated the Iressa quandary

By Paul Goldberg

Free In the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC

In Brief

Chika Madu named director of Northwell’s Staten Island University Hospital Florina Cancer Center

Christian Rolfo named director of Ohio State Division of Medical Oncology

ASH recognizes 10 hematologists with 2024 honorific awards

Fred Hutch announces eight recipients of 2024 Eddie Méndez Scholar Award

NCCN patient resources receive Hemes Creative Award, Communicator Award, Viddy Award

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

Wistar Institute receives $10M donation

MSU receives $1.1M grant to support mesothelioma caregivers

Clinical Roundup

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

ASTRO updates guideline on radiation therapy for HPV-related throat cancer

Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

Combination targeted treatment produces lasting remissions in resistant aggressive DLBCL in phase Ib/II study

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

New 3D technique reveals precancerous pancreatic lesions

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Drugs & Targets

FDA approves Keytruda combination for primary advanced or recurrent endometrial carcinoma

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

FDA clears IND application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 43 - November 15, 2024